RPL36A (Ribosomal Protein L36a) is a component of the 60S ribosomal subunit. RPL36A is involved in translation elongation and has been implicated in cancer progression. In neurodegeneration, altered ribosomal protein expression affects protein homeostasis.
Ribosomal Protein L36a (RPL36A) is a component of the large (60S) ribosomal subunit in eukaryotic cells. The RPL36A gene encodes a protein of approximately 12.4 kDa that is expressed across various tissue types. RPL36A is one of the smaller ribosomal proteins and is located at the interface between the two subunits, where it participates in the conformational changes required for translation elongation.
The large ribosomal subunit is responsible for the peptidyl transferase reaction, which forms the peptide bonds between amino acids during protein synthesis. RPL36A contributes to this process by helping to stabilize the binding of tRNA molecules at the A-site, P-site, and E-site of the ribosome. The protein is involved in the translocation step, where the ribosome moves along the mRNA, shifting the tRNA molecules between these sites.
While RPL36A is not as extensively studied as some other ribosomal proteins, research has shown that altered expression of RPL36A can impact cellular function. Studies have detected elevated RPL36A expression in certain cancers, suggesting it may play a role in tumor progression. In neurons, where precise regulation of protein synthesis is critical for synaptic function and plasticity, alterations in ribosomal protein composition can disrupt the delicate balance of protein homeostasis that is essential for neuronal survival.
RPL36A is a small protein with basic residues that interact with the 28S rRNA. The protein contributes to the subunit interface.
RPL36A is a component of the 60S ribosomal subunit involved in translation elongation and peptidyl transferase activity.
Altered RPL36A expression has been reported in cancer. Ribosomal dysfunction contributes to neurodegeneration.
No direct therapeutic targeting. RPL36A's role in cancer is being investigated.
The study of Ribosomal Protein L36A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.